Paranmycin Compounds for Bacterial Infection Treatment – Specifically MRSA

Technical Summary

•  Dr. Tom Chang of the Chemistry/Biochemistry department at Utah State University have developed novel paranmycin compounds and associated treatment methods.

•  Many aminoglycoside compounds, of which paranmycin compounds are included, have long been used as bactericidal drugs. Unlike many antibiotics, aminoglycosides have a broad-spectrum activity against both gram positive and negative bacteria. Clinical usage of aminoglycosides has been limited to serious infections due to resistant bacteria. To revive the effectiveness of aminoglycoside compounds, novel paranmycin compounds were developed.

Commercial Applications

•  Novel antibacterial compounds effective again resistant gram positive and gram negative bacterial infections.

 

Competitive Advantages

•  More effective than methicillin, penicillin, and amoxicillin

•  Multiple administration methods:

•  Topical application

•  Intravenous (IV)

•  Oral administration

•  Treats both gram positive and gram negative bacteria

•  Comparable gram positive kill rate to deptomycin and linezolid

 

Additional Information

 

 

References

•  US Patent 7,371,733

 

Related Technologies

•  New Synthetic Antifungal Agents (P10039)

•  Aminoglycoside and Azole Compositions and Methods (P13013)

•  Aminoglycosides, Methods of Synthesis and Associated Applications (P14062)

 

Patent Information:
Category(s):
Biotech/Biomedical
For Information, Contact:
Christian Iverson
Utah State University
435-797-9620
christian.iverson@usu.edu
Inventors:
Cheng-Wei Chang
Keywords: